MetaVia Inc. (NASDAQ:MTVA – Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 56,090 shares, a decrease of 43.2% from the October 15th total of 98,690 shares. Based on an average daily trading volume, of 70,460 shares, the short-interest ratio is currently 0.8 days. Approximately 1.1% of the company’s stock are sold short.
MetaVia Stock Performance
MTVA opened at $1.25 on Wednesday. MetaVia has a fifty-two week low of $0.97 and a fifty-two week high of $13.42. The firm has a 50-day moving average of $1.44 and a 200 day moving average of $1.60. The firm has a market cap of $8.43 million, a P/E ratio of -0.39 and a beta of 1.24.
MetaVia (NASDAQ:MTVA – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.04. Equities research analysts predict that MetaVia will post -2.79 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on MetaVia
About MetaVia
MetaVia, Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, including obesity, metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. The company’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being studied for obesity, and DA-1241, an investigational GPR119 agonist being developed for MASH and type 2 diabetes. These candidates are experimental and have not been established as approved treatments.
Further Reading
- Five stocks we like better than MetaVia
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
